MK-4884

DRUG2 trials

Sponsors

Fujita Tomoko, Merck Sharp & Dohme LLC

Conditions

Malignant Neoplasmadvanced/metastatic solid tumors

Phase 1

A Phase 1 Study of MK-4884 for Advanced/Metastatic Solid Tumors

Active, not recruitingJPRN-jRCT2031260123

Fujita Tomokoadvanced/metastatic solid tumors

Start: 2026-06-15Target: 6Updated: 2026-06-29

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

RecruitingNCT07600749

Merck Sharp & Dohme LLCMalignant Neoplasm

Start: 2026-06-18End: 2029-10-04Target: 120Updated: 2026-09-03